NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone“) is a pioneering biopharmaceutical company developing regenerative medicine therapies. As you can see by the chart, the Company caught fire in January 2023, blasting from the price per share wasteland to surge in one day over 50%. The annual range is CDN0.10 to CDN1.15. With a daily average volume of 115k, add liquidity to this biopharma’s list of positives.
With a minimum of pharma-speak, NRX is a pharmaceutical company developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.
Let’s get a research opinion;
“Shares appear to be priced significantly below absolute and comparative metrics. While our CAD$4.00 price target is based on discounted future earnings, a comparable analysis looking at biopharma companies co-developing specialized treatment platforms and treatments suggests the share price at the time of breakeven would be >CAD$2.50.” (Litchfield Hills).
I also found a great article that digs into the Company to potentially give confidence to buy some. A few highlights of the NATURE piece;
- At the forefront of developing exosomes into next-generation nanocarriers for drug delivery.
- Exosomes play an essential biological role in intercellular communication and transmission of macromolecules between cells.
- Vehicles for the delivery of active pharmaceutical ingredients (APIs), from small molecules and peptides to proteins and nucleic acids, as an alternative to other kinds of nanocarriers such as lipid vesicles and cell-based gene therapies.
- They do not seem to elicit the strong immune responses that often hamper allogeneic cell-based therapies, which are used to deliver therapeutic molecules and genes to patients.
- NurExone’s ambitious goal is to market a novel treatment for acute spinal cord injuries (SCIs) derived from the ExoTherapy platform, ExoPTEN.
- NurExone’s ambitious goal is to market a novel treatment for acute spinal cord injuries (SCIs) derived from the ExoTherapy platform, ExoPTEN.
The complete text of this highly informative piece is here.
NRX is undergoing an OTCQB listing, which will open the Company to US and global investors.
Mr. Yoram Drucker, chairman of NurExone’s board, commented, “Expanding our presence to the OTCQB underscores our commitment to enhancing investor engagement and liquidity for our shareholders. OTCQB listing will offer US investors an easy way to invest in NurExone. As pioneers in the development of exosome-loaded nanodrugs for a wide range of clinical indications, we are pleased to offer broader opportunities for the investing public to join us on this innovative journey”.
These observations should be enough for investors to consider a severe look.
There’s also Orphan Drug Designation, which is the building of a state-of-the-art research and development facility.
And that’s just so far this year. Stay tuned for more. Lots more.
Bob Beaty
For over 30 years, Bob Beaty has been explaining concepts and companies to the global investment community. One of the original writers for Jim Cramer’s Thestreet.com, he also wrote for AOL (Can/US), the Globe and Mail, and the Huffington Post. Over that period, he illuminated small-cap companies to investors with wit and pith but mostly opinion and facts. Investing should be fun. Pedantic, staid content is no fun.
Before embarking on his writing career, Bob had a successful international journey in the finance industry. He served as a broker, derivatives product manager, and a Director of London's Credit Suisse subsidiary. His career spanned across major financial hubs including Toronto, Vancouver, and the UK, giving him a unique global perspective. (He is still fondly remembering those English client lunches.)
Other than everything Groucho Marx and George Carlin ever said, Bob lives by a simple credo;
‘Never do anything the person standing in front of you can't understand.’ Hunter S. Thompson.
Let’s go.
